Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,840.00+1.10%ETH$2,504.38+3.44%GOLD$4,420.40+0.30%OIL$99.44-2.97%
Smart Investors Daily
Bio-Techne Corporation logo

NASDAQ · TECH

Bio-Techne Corporation

Healthcare · Biotechnology

$72.08

Down-$0.17 (-0.24%)

Updated Sep 11, 2026, 11:21 AM

SID Score

5.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
9.45B
P/E ratio
120.15
Dividend yield
0.44%
52-week range
$43.20 – $72.62
Volume
3.82M
Avg. volume
2.21M

Price performance

TECH price history

1M range · 20 trading sessions · Daily adjusted prices

TECH closed at $72.08 after 20 trading sessions, down 0.12% for the selected period.

Last close
$72.08
Period change
-0.12%
Period low
$72.08
Period high
$72.48
Daily close
View OHLC price history
TECH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$72.28$72.325$72.08$72.083.82M
Sep 9, 2026$72.30$72.365$72.23$72.251.99M
Sep 8, 2026$72.37$72.46$72.29$72.312.07M
Sep 4, 2026$72.40$72.48$72.40$72.431.86M
Sep 3, 2026$72.36$72.58$72.32$72.452.54M
Sep 2, 2026$72.20$72.38$72.20$72.301.66M
Sep 1, 2026$72.36$72.39$72.14$72.182.9M
Aug 31, 2026$72.375$72.41$72.30$72.312.2M
Aug 28, 2026$72.40$72.48$72.32$72.351.63M
Aug 27, 2026$72.38$72.50$72.35$72.471.68M
Aug 26, 2026$72.33$72.40$72.325$72.381.39M
Aug 25, 2026$72.35$72.38$72.28$72.331.9M
Aug 24, 2026$72.29$72.415$72.27$72.392M
Aug 21, 2026$72.32$72.35$72.27$72.323.96M
Aug 20, 2026$72.36$72.51$72.23$72.283.54M
Aug 19, 2026$72.40$72.555$72.38$72.482.51M
Aug 18, 2026$72.41$72.515$72.22$72.222.56M
Aug 17, 2026$72.22$72.62$72.22$72.392.93M
Aug 14, 2026$72.23$72.425$72.07$72.402.01M
Aug 13, 2026$72.21$72.305$72.055$72.171.98M

Latest TECH news

The latest Smart Investors Daily articles mentioning TECH.

Stock researchCompany · Overview

TECH research

Overview

Company profile and research snapshot.

Company profile

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$69.67
Implied upside
—
Analysts
23
TECH recent ratings
DateFirmRatingTarget
Aug 13, 2026Wells FargoEqual-Weight—
Jul 9, 2026RBC CapitalSector Perform—
Jun 30, 2026BenchmarkHold—
Jun 30, 2026TD CowenHold—
Jun 29, 2026CitigroupNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals

Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By